{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:28:25Z","timestamp":1792013305221,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.intimp.2023.110090","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T07:01:47Z","timestamp":1681110107000},"page":"110090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["IFABP2 as a new prognostic biomarker for secondary non-response in rheumatoid arthritis"],"prefix":"10.1016","volume":"119","author":[{"given":"Oscar","family":"Zaragoza-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse Adriana","family":"Guti\u00e9rrez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Brice\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Rafael","family":"Villafan-Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Eduardo","family":"Navarro-Zarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isela","family":"Parra-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramc\u00e9s","family":"Falf\u00e1n-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Paola","family":"Guzm\u00e1n-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9636","key":"10.1016\/j.intimp.2023.110090_b0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"issue":"9410","key":"10.1016\/j.intimp.2023.110090_b0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: doubl\u00e9-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2023.110090_b0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.intimp.2023.110090_b0020","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s10067-010-1454-y","article-title":"Contribution of HLA-DRBI*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis","volume":"29","author":"Mori","year":"2010","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110090_b0025","doi-asserted-by":"crossref","first-page":"13760","DOI":"10.3390\/ijms160613760","article-title":"Pharmacogenomics of methotrexate membrane transport pathway: Can clinical response to methotrexate in rheumatoid be predicted?","volume":"16","author":"Lima","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.110090_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1645-5","article-title":"Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)","volume":"20","author":"Sergeant","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2023.110090_b0035","doi-asserted-by":"crossref","unstructured":"P.W. Zhao, W.G. Jiang, L. Wang, Z.Y. Jiang, Y.X. Shan, Y.F. Jiang, Plasma levels of IL-37 and correlation with TNF-\u03b1, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis, PLoS ONE 9(5) (2014) e95346, doi: 10.1371\/journal.pone.0095346.","DOI":"10.1371\/journal.pone.0095346"},{"issue":"6","key":"10.1016\/j.intimp.2023.110090_b0040","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jbspin.2010.02.018","article-title":"Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis","volume":"77","author":"Maillefert","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2023.110090_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/4693870","article-title":"Tobacco-derived lipopolysaccharide, not microbial translocation, as a potential contributor to the pathogenesis of rheumatoid arthritis","volume":"2019","author":"Meyer","year":"2019","journal-title":"Mediators Inflamm."},{"issue":"7","key":"10.1016\/j.intimp.2023.110090_b0050","first-page":"864","article-title":"Intestinal barrier dysfunction play an integral role in arthritis pathology and can be targeted to ameliorate disease","volume":"2","author":"Matei","year":"2021","journal-title":"Med. (N.Y.)"},{"key":"10.1016\/j.intimp.2023.110090_b0055","article-title":"Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation which are reversed by inflammation control","author":"Audo","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2023.110090_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/6839356","article-title":"Oral and intestinal bacterial substances associated with disease activities in patients with rheumatoid arthritis: a cross-sectional clinical study","volume":"2022","author":"Kitamura","year":"2022","journal-title":"J. Immunol. Res."},{"issue":"12","key":"10.1016\/j.intimp.2023.110090_b0065","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/1346-8138.14647","article-title":"Intestinal barrier integrity in patients with plaque psoriasis","volume":"45","author":"Sikora","year":"2018","journal-title":"J. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.110090_b0070","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm8071021","article-title":"Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis","volume":"8","author":"Sikora","year":"2019","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.110090_b0075","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2016-210000","article-title":"Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis","volume":"76","author":"Ciccia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"#cr-split#-10.1016\/j.intimp.2023.110090_b0080.1","doi-asserted-by":"crossref","unstructured":"D. Aletaha, T. Neogi, A.J. Silman, J. Funovits, D.T. Felson, C.O. Bingham 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative, Arthritis Rheum. 62","DOI":"10.1002\/art.27584"},{"key":"#cr-split#-10.1016\/j.intimp.2023.110090_b0080.2","doi-asserted-by":"crossref","unstructured":"(9) (2010) 2569-2581, doi: 10.1002\/art.27584.","DOI":"10.1002\/ejic.201000297"},{"key":"10.1016\/j.intimp.2023.110090_b0085","doi-asserted-by":"crossref","unstructured":"K. Forslind, I. Hafstr\u00f6m, M. Ahlm\u00e9n, B. Svensson, BARFOT Study Group, Sex: a major predictor of remission in early rheumatoid arthritis? Ann. Rheum. Dis. 66(1) (2007) 46\u201352, doi: 10.1136\/ard.2006.056937.","DOI":"10.1136\/ard.2006.056937"},{"issue":"8","key":"10.1016\/j.intimp.2023.110090_b0090","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2021-220202","article-title":"Primary and secondary non-response: in need of operational definitions in observational studies","volume":"80","author":"Vallejo-Yag\u00fce","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2023.110090_b0095","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugue","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"#cr-split#-10.1016\/j.intimp.2023.110090_b0100.1","doi-asserted-by":"crossref","unstructured":"D. Szklarczyk, A.L. Gable, K.C. Nastou, D. Lyon, R. Kirsch, S. Pyysalo, et al., The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets, Nucleic Acids Res. 49","DOI":"10.1093\/nar\/gkab835"},{"key":"#cr-split#-10.1016\/j.intimp.2023.110090_b0100.2","doi-asserted-by":"crossref","unstructured":"(D1) (2021) D605-D612, doi: 10.1093\/nar\/gkaa1074.","DOI":"10.1093\/nar\/gkaa1074"},{"issue":"15","key":"10.1016\/j.intimp.2023.110090_b0105","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/bmm-2020-0284","article-title":"Elevated expression of FABP4 is associated with disease activity in rheumatoid arthritis patients","volume":"14","author":"Chen","year":"2020","journal-title":"Biomark. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.110090_b0110","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.mayocp.2017.05.009","article-title":"Prediction of response to targeted treatment in rheumatoid arthritis","volume":"92","author":"Wijbrandts","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2023.110090_b0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cccn.2004.09.001","article-title":"Fatty acid-binding proteins as plasma markers of tissue injury","volume":"352","author":"Pelsers","year":"2005","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.intimp.2023.110090_b0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1023\/B:DDAS.0000011604.45531.2c","article-title":"Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis","volume":"49","author":"Carneiro-Filho","year":"2004","journal-title":"Dig. Dis. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2023.110090_b0125","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s10620-005-9058-0","article-title":"Confirmation and prevention of intestinal barrier dysfunction and bacterial translocation caused by methotrexate","volume":"51","author":"Song","year":"2006","journal-title":"Dig. Dis. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2023.110090_b0130","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3390\/biom10111479","article-title":"DMARDs-gut microbiota feedback: implications in the response to therapy","volume":"10","author":"Zaragoza-Garc\u00eda","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2023.110090_b0135","doi-asserted-by":"crossref","unstructured":"A. Kerschbaumer, A. Sepriano, S.A. Bergstra, J.S. Smolen, D. van der Heijde, R. Caporali, et al., Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann. Rheum. Dis. (2022) ard-2022-223365, doi: 10.1136\/ard-2022-223365.","DOI":"10.1136\/ard-2022-223365"},{"issue":"6","key":"10.1016\/j.intimp.2023.110090_b0140","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1511","article-title":"Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis","volume":"8","author":"He","year":"2022","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.intimp.2023.110090_b0145","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/annrheumdis-2021-221386","article-title":"Higher serum levels of short-chain fatty acids are associated with non-progression to arthritis in individuals at increased risk of RA","volume":"81","author":"Martinsson","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"17","key":"10.1016\/j.intimp.2023.110090_b0150","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1111\/bph.15852","article-title":"Short-chain fatty acids regulate B cells differentiation via FFAR2 to alleviate rheumatoid arthritis","volume":"179","author":"Yao","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110090_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jksus.2021.101545","article-title":"Propionate restores disturbed gut microbiota induced by methotrexate in Rheumatoid Arthritis: from clinic to experiments","volume":"33","author":"Fan","year":"2021","journal-title":"J. King Saud. Univ. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.110090_b0160","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cyto.2013.05.001","article-title":"The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels","volume":"64","author":"Andr\u00e9s Cerezo","year":"2013","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.intimp.2023.110090_b0165","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/rheumatology\/kes177","article-title":"Peroxisome proliferator-activated receptor-gamma expression in monocytes\/macrophages from rheumatoid arthritis patients: relation to disease activity and therapy efficacy-a pilot study","volume":"51","author":"Palma","year":"2012","journal-title":"Rheumatology (Oxford)"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923004113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923004113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:33:05Z","timestamp":1785771185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923004113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":35,"alternative-id":["S1567576923004113"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110090","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFABP2 as a new prognostic biomarker for secondary non-response in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110090"}}